The phylogeny of yellow fever virus 17D vaccines

被引:24
|
作者
Stock, Nina K. [1 ]
Boschetti, Nicola [2 ]
Herzog, Christian [2 ]
Appelhans, Marc S. [3 ]
Niedrig, Matthias [1 ]
机构
[1] Robert Koch Inst, D-13353 Berlin, Germany
[2] Crucell Switzerland AG, CH-3018 Bern, Switzerland
[3] Leiden Univ, Netherlands Ctr Biodivers Nat, Sect NHN, NL-2300 RA Leiden, Netherlands
关键词
Yellow fever; 17D; Vaccine; Phylogeny; Full genome; NUCLEOTIDE-SEQUENCE; VISCEROTROPIC DISEASE; IMMUNOGENICITY; SAFETY; STRAIN;
D O I
10.1016/j.vaccine.2011.12.057
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In recent years the safety of the yellow fever live vaccine 17D came under scrutiny. The focus was on serious adverse events after vaccinations that resemble a wild type infection with yellow fever and whose reasons are still not known. Also the exact mechanism of attenuation of the vaccine remains unknown to this day. In this context, the standards of safety and surveillance in vaccine production and administration have been discussed. Therein embodied was the demand for improved documentation of the derivation of the seed virus used for yellow fever vaccine production. So far, there was just a historical genealogy available that is based on source area and passage level. However, there is a need for a documentation based on molecular information to get better insights into the mechanisms of pathology. In this work we sequenced the whole genome of different passages of the YFV-17D strain used by Crucell Switzerland AG for vaccine production. Using all other publically available 17D full genome sequences we compared the sequence variance of all vaccine strains and oppose a phylogenetic tree based on full genome sequences to the historical genealogy. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:989 / 994
页数:6
相关论文
共 50 条
  • [1] Safety of 17D derived yellow fever vaccines
    Domingo, Cristina
    Niedrig, Matthias
    [J]. EXPERT OPINION ON DRUG SAFETY, 2009, 8 (02) : 211 - 221
  • [2] 17D Yellow Fever Virus Vaccine
    Monath, Thomas P.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2013, 89 (06): : 1225 - 1225
  • [3] The yellow fever 17D virus as a platform for new live attenuated vaccines
    Bonaldo, Myrna C.
    Sequeira, Patricia C.
    Galler, Ricardo
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (05) : 1256 - 1265
  • [4] 17D Yellow Fever Virus Vaccine Response
    Edupuganti, Srilatha
    Mulligan, Mark J.
    Eidex, Rachel B.
    Cetron, Martin
    Marfin, Anthony A.
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2013, 89 (06): : 1226 - 1227
  • [5] Comparison of the immunogenicity and safety of two 17D yellow fever vaccines
    Lang, J
    Zuckerman, J
    Clarke, P
    Barrett, P
    Kirkpatrick, C
    Blondeau, C
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1999, 60 (06): : 1045 - 1050
  • [6] Genetic variability among yellow fever virus 17D substrains
    Galler, R
    Post, PR
    Santos, CND
    Ferreira, II
    [J]. VACCINE, 1998, 16 (9-10) : 1024 - 1028
  • [7] Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections
    Neyts, J
    Meerbach, A
    McKenna, P
    DeClercq, E
    [J]. ANTIVIRAL RESEARCH, 1996, 30 (2-3) : 125 - 132
  • [8] Generation and Application of a Luciferase Reporter Virus Based on Yellow Fever Virus 17D
    Dan Li
    Jing-Long Ye
    Zhong-Yu Liu
    [J]. Virologica Sinica., 2021, 36 (06) - 1464
  • [9] Generation and Application of a Luciferase Reporter Virus Based on Yellow Fever Virus 17D
    Li, Dan
    Ye, Jing-Long
    Liu, Zhong-Yu
    [J]. VIROLOGICA SINICA, 2021, 36 (06) : 1456 - 1464
  • [10] A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins
    Bredenbeek, PJ
    Molenkamp, R
    Spaan, WJM
    Deubel, V
    Marianneau, P
    Salvato, MS
    Moshkoff, D
    Zapata, J
    Tikhonov, C
    Patterson, J
    Carrion, R
    Ticer, A
    Brasky, K
    Lukashevich, IS
    [J]. VIROLOGY, 2006, 345 (02) : 299 - 304